Neumora Therapeutics, Inc. Common Stock

NASDAQ:NMRA

Biotechnology

Healthcare
$0.37 -6.21%

-$0.10 today

Market cap
$69.21M
Beta
2.76
P/E (TTM)
-1.2
EPS (TTM)
-$1.24
52W Low $0.72High $3.65

Volume 1.50M

Average 2.02M

NMRA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Neumora Therapeutics, Inc. Common StockNASDAQ: NMRA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $53.46M (cash outflow) fell 21.4% year over year, behind the -13.8% change in trailing-twelve-month net income. Sequentially, it fell 10.1% from the prior quarter. Over 3 fiscal years it compounded at +21.9% a year.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 9 analysts of -$179.26M (-24.3%) for the fiscal year ending Dec 2026, a slowdown from the -2.8% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$53.46M-10.1% QoQ
Last fiscal yearDec 2025
-$236.93M-2.8% YoY
LTMMar 2026
-$222.39M-13.8% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.4%-18.6%+2.7 pp
1 year-2.8%-24.3%-21.5 pp
3-year CAGR+21.9%-23.6%-45.5 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(236.93M) USD
Year-over-year change
+2.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How NMRA compares with its peers on the latest reported figures

  • NMRA's LTM Mar 2026 net income of $222.39M is the 3rd largest of the 10 companies compared; the peer median is $151.18M.
  • Its year-over-year change of -13.8% is the 9th highest of 10, against a peer median of +21.3%.
  • Over three fiscal years its annual growth of +21.9% compares with a peer median of +9.2%.
NMRA Competitors Peer median
Net Income for NMRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALMSAlumis Inc. Common StockLTM Jun 2026$438.96M +92.9%+29.5%5933.5%
AUTLAutolus Therapeutics plcLTM Mar 2026$288.97M +21.3%+24.5%312.1%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$222.39M -13.8%+21.9%—
BCYCBicycle Therapeutics plcLTM Mar 2026$218.8M +7.2%+24.8%344.6%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$160.9M -8.8%+9.2%182.3%
PRTAProthena Corporation plcLTM Mar 2026$151.18M +37.1%+27.8%260.9%
ADCTADC Therapeutics S.A.LTM Mar 2026$136.99M -8.6%-3.2%173.0%
OMEROmeros CorporationLTM Mar 2026$81.36M +148.9%-73.6%822.4%
FULCFulcrum Therapeutics, Inc.LTM Mar 2026$76.12M +14824.7%-12.0%—
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$26.09M -85.3%-21.0%37.5%
Peer median (excluding NMRA) $151.18M+21.3%+9.2%286.5%

Competitors are the stored peer set for NMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(237.31M)(130.9M)(235.93M)(243.79M)(236.93M)
Depreciation & Amortization538K594K668K631K208K
Deferred Income Tax(53K)0000
Stock-Based Compensation4.27M8.3M17.24M39.99M29.88M
Change in Working Capital(961K)(6.95M)(8.9M)22.64M(437K)
Accounts Receivables00000
Inventory00000
Accounts Payables(759K)(1.25M)(581K)2.87M71K
Other Working Capital(202K)(5.7M)(8.32M)19.76M(508K)
Other Non-Cash Items158.09M14.06M63.64M(1.78M)841K
Operating Cash Flow(75.42M)(114.9M)(163.28M)(182.94M)(206.44M)
Capital Expenditures(817K)(511K)(117K)00
Acquisitions (Net)000(775K)0
Purchases of Investments0(226.37M)(109.07M)(312.22M)(85.8M)
Sales of Investments071.87M178.17M242.44M251.17M
Other Investing Activities0(13M)(4.59M)03.15M
Investing Cash Flow(817K)(168.01M)64.39M(70.56M)168.52M
Debt Repayment000057.16M
Common Stock Issued960K0233.38M13.69M19.93M
Common Stock Repurchased00(491K)00
Dividends Paid00000
Other Financing Activities1.37M3.53M(948K)7.91M0
Financing Cash Flow293.51M115.74M231.94M21.6M77.09M
Effect of Forex Changes00000
Net Change in Cash217.27M(167.17M)133.05M(231.89M)39.17M
Free Cash Flow(76.24M)(115.41M)(163.4M)(182.94M)(206.44M)

Neumora Therapeutics, Inc. Common Stock

NASDAQ:NMRA

Intrinsic Alpha fair value

Locked

Current Price

$0.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.